NDFS17 Video: CIRM Translation & Clinical Development Grants for Cell & Gene Therapy
Dr. Abla Creasey discusses non-dilutive funding opportunities at the California Institute for Regenerative Medicine, which funds stem cell R&D.
Entries by Ayal Ronen
NDFS17 Video: SBIR/STTR Grants & Contracts at NIAID & NIH
Dr. Natalia Kruchinin discusses non-dilutive funding opportunities at NIAID and NIH.
NDFS17 Video: Abalone Bio’s Pathway to Granting Success
Nick Damiano, co-founder and CEO of Abalone Bio, discusses the company’s success with non-dilutive funding. Abalone Bio is the first company to win funding from FreeMind Investments.
NDFS17 Video: Zenflow’s Path to Non-Dilutive Funding Success
Nick Damiano, co-founder and CEO of Zenflow, discusses the company’s success with non-dilutive funding.
NDFS17 Video: Inflammatix: Our Road to Success with Non-Dilutive Funding
Tim Sweeney, MD, PhD, is co-founder and CEO of Inflammatix, discusses the company’s success with non-dilutive funding.
NDFS17 Video: Introducing FreeMind Investments
Ram May-Ron, Managing Partner of the FreeMind Group, Dongkyu “Theirry” Uh, President of Daewoong Innovation Holdings, and Ayal Ronen, Chief Business Officer of the FreeMind Group discuss our new venture capital fund, FreeMind Investments.
NIAID BAA January 2022
The National Institute of Allergy & Infectious Diseases (NIAID) has just published a Broad Agency Announcement (BAA). This BAA contains four distinct Research Areas: Vaccines, Therapeutics, and In-Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections and Emerging Infectious Diseases, and Antivirals for Specific RNA Viral Families of Pandemic Potential.
FreeMind can help you apply for these funds or for other non-dilutive grants and contracts. FreeMind will host a webinar about the BAA on February 7, at 1:00 PM EST.